New research on a novel approach to identifying potential anticancer drug combinations revealed that combining cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene. David F. Stern, Ph.D., professor of pathology at Yale University School of Medicine in New Haven, Conn., and colleagues reported these data in iCancer Discovery/i, ...Sunday, 16 December 2012
Potential Drug Combos for Difficult-to-Treat Melanomas: Research
New research on a novel approach to identifying potential anticancer drug combinations revealed that combining cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene. David F. Stern, Ph.D., professor of pathology at Yale University School of Medicine in New Haven, Conn., and colleagues reported these data in iCancer Discovery/i, ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment